August 25, 2026 06:22 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Supreme Court directs Tarun Tejpal to surrender within two weeks | Supreme Court notice to 20 rebel TMC MPs in disqualification plea | ‘Reservation for poor, not caste’: Stir at Delhi’s Jantar Mantar | Dalit woman 'gangrape-murder' shocker in Karnataka: 4 arrested after body found in well | India dismisses Pakistan's 'frustration' over US envoy's J&K remark | Centre denies US visit clearance to Telangana CM Revanth Reddy, says programmes 'not appropriate' | Delhi Police register FIR in pellet gun case after Rahul Gandhi's sit-in | Rahul Gandhi stages dharna at Delhi police station over CJP protest crackdown, targets Amit Shah | CJP school tour turns chaotic in Jaipur: Cars vandalised, stones pelted as Ashutosh Ranka alleges BJP ‘goons’ attack | Vande Mataram row: Kangana Ranaut slams Sharmila Tagore, says ‘come out of Hindu-Muslim mindset’
Stock Market
Representational Photo: ChatGPT

Bloodbath on Dalal Street! Sensex crashes over 700 points, Nifty down 200 points amid market panic

| @indiablooms | Jan 08, 2026, at 02:08 pm

Mumbai/IBNS: The Indian stock market witnessed a sharp sell-off on Thursday, with the BSE Sensex plummeting over 700 points and the NSE Nifty 50 sliding more than 200 points, media reports said.

The indices remained under pressure throughout the morning session, with Sensex touching an intraday low of 84,230.

Among the notable laggards in the Nifty 500 were Signature Global, Hindustan Zinc, National Aluminium, NMDC, Hindustan Copper, JSL and GMDC.

At around 1:30 pm, Punjab National Bank shares fell 2.13%, while Apex Frozen Foods plunged 7.56%, intensifying the market slide.

In the morning, shares of Panacea Biotec Ltd. surged around 9 per cent on Thursday after the pharmaceutical and vaccine maker announced the completion of enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll.

The company has enrolled a total of 10,335 participants in the late-stage trial, marking a key milestone in the development of India’s indigenous dengue vaccine.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.